Trial · NCT07877649
Longitudinal Registry of Difficult-to-Treat Inflammatory Bowel Disease
NCT07877649, Not yet recruiting, First Affiliated Hospital, Sun Yat-Sen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Longitudinal Registry of Difficult-to-Treat Inflammatory Bowel Disease. Trials, record NCT07877649. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07877649
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Longitudinal Registry of Difficult-to-Treat Inflammatory Bowel Disease
- NCT number
- NCT07877649
- Status
- Not yet recruiting
- Enrollment
- 2,000 participants, estimated
- Lead sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Conditions
- Inflammatory Bowel Diseases (IBD), Crohn Disease, Colitis, Ulcerative
- Interventions
- Routine IBD Management and Advanced-Therapy Exposure
- First posted
- 2026-10-16
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Prevalence of Difficult-to-Treat Inflammatory Bowel Disease | Baseline | Proportion of evaluable participants who meet the prespecified operational criteria for difficult-to-treat inflammatory bowel disease (DTT-IBD) at baseline. Individual DTT-IBD domains and overlapping domains will be reported separately. |
| Primary | Cumulative Incidence of Newly Developed Difficult-to-Treat Inflammatory Bowel Disease | Up to 36 months | Among participants who do not meet DTT-IBD criteria at baseline, the proportion who first meet the prespecified operational criteria for DTT-IBD during longitudinal follow-up. |
| Secondary | Time to DTT-IBD | Up to 36 months | Time from initiation of the first advanced therapy to the first date on which the participant meets prespecified DTT-IBD criteria. |
| Secondary | Objective Disease Control After DTT-IBD | 12 months after first meeting DTT-IBD criteria | Proportion of participants achieving prespecified corticosteroid-free objective disease control after first meeting DTT-IBD criteria. |
| Secondary | Advanced-Therapy Failure | Up to 36 months | Proportion of participants experiencing at least one subsequent objectively supported advanced-therapy failure during follow-up. |
| Secondary | IBD-related Hospitalization | Up to 36 months | Proportion of participants experiencing at least one unplanned hospitalization primarily attributable to active inflammatory bowel disease or an IBD-related complication. |
| Secondary | IBD-related Surgery | Up to 36 months | Proportion of participants undergoing an IBD-related intestinal resection, diversion, or other prespecified major IBD-related surgical procedure. |
| Secondary | New or Worsening Irreversible Bowel Damage | Up to 36 months | Proportion of participants developing a new or clearly worsened prespecified irreversible structural bowel-damage event after baseline. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07877649
GET https://conductscience.org/api/trials/v1/NCT07877649/registered